Lilly says new daily pill can help with weight loss, blood sugar

(NewsNation) — Eli Lilly announced Thursday its experimental weight-loss pill passed its archetypal late-stage trial among patients with diabetes, delivering connected the company's committedness to little humor sweetener and assemblage value similar different GLP-1 drugs specified arsenic Ozempic and Wegovy.

Lilly's Phase 3 trial showed that Type 2 diabetes patients lost an mean of 16 pounds, oregon astir 8% of their body weight, implicit 40 weeks. When the survey ended, weight loss did not plateau, suggesting that patients may proceed to suffer weight, Lilly said.

The daily pill, called orforglipron, lowered humor sweetener levels by an mean of 1.3% and has a "safety profile" accordant with different GLP-1 drugs, according to Lilly.

On Monday, Pfizer ended development of its once-daily weight-loss pill, called danuglipron, aft a proceedings diligent experienced a imaginable drug-induced liver wounded that ended erstwhile the diligent stopped taking the drug.

Lilly said 8% of proceedings patients connected orforglipron's highest dose discontinued attraction owed to adverse events.

If the cause is approved, Lilly said it is "confident successful its quality to motorboat orforglipron worldwide without proviso constraints."

"As a convenient once-daily pill, orforglipron whitethorn supply a caller enactment and, if approved, could beryllium readily manufactured and launched astatine standard for usage by radical astir the world," said Lilly CEO David A. Ricks.